생물학적 피부 대체물 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 유형별, 용도별, 최종사용자별, 지역별, 경쟁별(2020-2030년)

Biological Skin Substitutes Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Application, By End User, By Region and Competition, 2020-2030F

US $ 4,500 ￦ 6,286,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500 ￦ 7,682,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000 ￦ 11,175,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

한글목차

생물학적 피부 대체물 세계 시장 규모는 2024년 3억 4,147만 달러에서 2030년에는 5억 5,850만 달러에 달할 것으로 예상되며, 예측 기간 동안 8.52%의 CAGR로 성장할 것으로 예상됩니다.

시장 성장의 원동력은 특히 당뇨병성 궤양, 욕창, 화상 등 만성 상처에 대한 고급 상처 치료에 대한 수요 증가입니다. 생물학적 피부 대체재는 치유를 촉진하고, 감염 위험을 최소화하며, 미용적 결과를 개선함으로써 기존 상처 치료에 대한 보다 효과적이고 생물학적 적합성이 높은 대안을 제공합니다. 이 시장은 재생의료, 조직공학, 줄기세포를 이용한 치료법과 같은 기술 발전으로 더욱 활성화되고 있습니다. 의료 시스템이 임상 결과 개선과 장기 치료 비용 절감에 중점을 두고 있는 가운데, 특히 복잡한 상처와 치유되지 않는 상처 관리에서 생물학적 피부 대체재가 각광을 받고 있습니다. 외과 수술의 증가, 인구의 고령화, 맞춤형 치료의 혁신이 시장 확대를 계속 촉진하고 있습니다.

시장 개요
예측 기간	2026-2030년
시장 규모 : 2024년	3억 4,147만 달러
시장 규모 : 2030년	5억 5,850만 달러
CAGR : 2025-2030년	8.52%
급성장 부문	만성 상처
최대 시장	북미

시장 촉진요인

재생의료의 발전

주요 시장 과제

높은 비용과 제한된 접근성

주요 시장 동향

개인화된 맞춤형 솔루션

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 세계의 생물학적 피부 대체물 시장 전망

• 시장 규모 및 예측
  • 금액별
• 시장 점유율과 예측
  • 종류별(인간 기증 조직 유래 제품, 무세포 동물 유래 제품, 생합성 제품)
  • 용도별(만성 상처, 급성 상처)
  • 최종사용자별(병원·진료소, 외래 진료 센터, 기타)
  • 기업별(2024)
  • 지역별
• 시장 맵

제6장 북미의 생물학적 피부 대체물 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 미국
  • 멕시코
  • 캐나다

제7장 유럽의 생물학적 피부 대체물 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 프랑스
  • 독일
  • 영국
  • 이탈리아
  • 스페인

제8장 아시아태평양의 생물학적 피부 대체물 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 한국
  • 일본
  • 호주

제9장 남미의 생물학적 피부 대체물 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 생물학적 피부 대체물 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 인수합병
• 제품 출시
• 최근 동향

제13장 Porter's Five Forces 분석

• 업계내 경쟁
• 신규 참여의 가능성
• 공급업체의 능력
• 고객의 능력
• 대체품의 위협

제14장 경쟁 구도

• Organogenesis Inc.
• Integra LifeSciences Corporation
• Smith & Nephew, plc
• Tissue Regenix Group
• MIMEDX Group, Inc.
• Stryker Corporation
• Vericel Corporation
• 3M Company
• Bio-Tissue, Inc.
• Stratatech Corporation

제15장 전략적 제안

제16장 조사 회사 소개 및 면책사항

ksm

영문 목차

영문목차

The Global Biological Skin Substitutes Market was valued at USD 341.47 million in 2024 and is projected to reach USD 558.50 million by 2030, growing at a CAGR of 8.52% during the forecast period. Market growth is being driven by increasing demand for advanced wound care, particularly for chronic wounds such as diabetic ulcers, pressure sores, and burn injuries. Biological skin substitutes offer a more effective and biologically compatible alternative to conventional wound care by enhancing healing, minimizing infection risks, and improving cosmetic outcomes. The market is further fueled by technological progress in regenerative medicine, tissue engineering, and stem cell-based therapies. As healthcare systems emphasize improved clinical outcomes and reduced long-term care costs, biological skin substitutes are gaining traction, especially in the management of complex or non-healing wounds. Increasing surgical procedures, an aging population, and innovation in personalized therapies continue to bolster market expansion.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 341.47 Million
Market Size 2030	USD 558.50 Million
CAGR 2025-2030	8.52%
Fastest Growing Segment	Chronic Wounds
Largest Market	North America

Key Market Drivers

Advancements in Regenerative Medicine

The growing integration of regenerative medicine in wound care is a key driver of the biological skin substitutes market. Chronic wounds such as diabetic foot ulcers and venous leg ulcers often resist healing through traditional methods. Regenerative medicine-leveraging stem cells, growth factors, and engineered tissue-enables the creation of substitutes that promote faster, more effective tissue repair. FDA approvals of various regenerative therapies highlight their clinical potential. These technologies improve healing outcomes and reduce complications, particularly among elderly patients and those with chronic conditions. The focus on biologically active, personalized solutions for difficult-to-heal wounds underscores the increasing relevance of regenerative therapies in the global market.

Key Market Challenges

High Costs and Limited Accessibility

The high production costs associated with biological skin substitutes pose a substantial barrier to market growth. These products require sophisticated manufacturing processes, such as cell harvesting and tissue engineering, which elevate their price. In low-income and resource-constrained healthcare systems, these costs often place advanced wound care out of reach. Additionally, infrastructure challenges in storing and administering these products-particularly in rural and under-resourced settings-limit their accessibility. Even in developed countries, limited insurance reimbursement and high out-of-pocket costs deter adoption. Addressing affordability and expanding access will be crucial for broader market penetration and improved patient outcomes worldwide.

Key Market Trends

Personalized and Custom-Made Solutions

Personalized wound care is emerging as a major trend in the biological skin substitutes market. Increasingly, treatments are being tailored to individual patient profiles, including autologous skin grafts derived from a patient's own cells. This reduces the risk of immune rejection and enhances healing, particularly for complex wounds or burn injuries. The growth of 3D bioprinting is further enabling the creation of skin substitutes that replicate the structure and functionality of natural skin. These personalized, patient-specific solutions offer superior biological compatibility and regeneration potential. As precision medicine gains momentum in wound care, the demand for custom skin substitutes is expected to accelerate significantly.

Key Market Players

• Organogenesis Inc.
• Integra LifeSciences Corporation
• Smith & Nephew, plc
• Tissue Regenix Group
• MIMEDX Group, Inc.
• Stryker Corporation
• Vericel Corporation
• 3M Company
• Bio-Tissue, Inc.
• Stratatech Corporation

Report Scope:

In this report, the Global Biological Skin Substitutes Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Biological Skin Substitutes Market, By Type:

• Human Donor Tissue-Derived Products
• Acellular Animal Derived Products
• Biosynthetic Products

Biological Skin Substitutes Market, By Application:

• Chronic Wounds
• Acute Wounds

Biological Skin Substitutes Market, By End User:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Biological Skin Substitutes Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Biological Skin Substitutes Market.

Available Customizations:

Global Biological Skin Substitutes Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

for export?

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Biological Skin Substitutes Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Human Donor Tissue-Derived Products, Acellular Animal Derived Products, Biosynthetic Products)
  • 5.2.2. By Application (Chronic Wounds, Acute Wounds)
  • 5.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.4. By Company (2024)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America Biological Skin Substitutes Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Biological Skin Substitutes Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Mexico Biological Skin Substitutes Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Canada Biological Skin Substitutes Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Biological Skin Substitutes Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Biological Skin Substitutes Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. Germany Biological Skin Substitutes Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Biological Skin Substitutes Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Biological Skin Substitutes Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Biological Skin Substitutes Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia-Pacific Biological Skin Substitutes Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Biological Skin Substitutes Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Biological Skin Substitutes Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. South Korea Biological Skin Substitutes Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. Japan Biological Skin Substitutes Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Biological Skin Substitutes Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. South America Biological Skin Substitutes Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Biological Skin Substitutes Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Biological Skin Substitutes Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Biological Skin Substitutes Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. Middle East and Africa Biological Skin Substitutes Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Biological Skin Substitutes Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Biological Skin Substitutes Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Biological Skin Substitutes Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porters Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Organogenesis Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Integra LifeSciences Corporation
• 14.3. Smith & Nephew, plc
• 14.4. Tissue Regenix Group
• 14.5. MIMEDX Group, Inc.
• 14.6. Stryker Corporation
• 14.7. Vericel Corporation
• 14.8. 3M Company
• 14.9. Bio-Tissue, Inc.
• 14.10. Stratatech Corporation

15. Strategic Recommendations

16. About Us & Disclaimer

관련자료